GSK, Bill and Melinda Gates Foundation, and Sanofi Pasteur form a joint initiative that will endeavour to make vaccines more resistant to heat.
The Vaccine Discovery Partnership (VxDP) is a novel funding programme initiated by the Bill & Melinda Gates Foundation to enhance innovation in the development of vaccines for global health. Under a Memorandum of Understanding (MoU) framework, the VxDP will oversee a range of projects with multiple industry partners. Projects funded through the VxDP will span preclinical to experimental Phase IIa trials. These projects may be of relatively high risk, such that they would be difficult for any one organisation to fund without the partnership. The Foundation will set aside funds to support pilot projects and partnering companies will contribute matching resources and expertise while also committing that advances will support those who need them most through global access provisions.
Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, the world's fourth-largest by prescription sales. Sanofi engages in the research and development,...
We are a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. Our products are used by millions of people around the world,...
Location | Worldwide |
Status | Announced
|
Value | USD 1.8 Million |
Sectors |